On March 17, 2010
More Delays on MannKind’s Inhaled Insulin: The Pros and Cons
Biotech company MannKind (MNKD)’s quest for approval of inhaled insulin drug Afrezza has attracted outspoken supporters and detractors — and this week’s complete response letter has them at each other’s throats again.
No tags for this post.
0 Comments